Objective: We report on our experience with the use of self–expandable metal stents for the treatment of extramural ureteral obstruction in patients with gynecologic cancer to restore ureteral patency and to alleviate the ureterectasis and hydronephrosis proximal to the ureteral narrowing.Methods: Fourteen women (mean age 48 years) with obstructive uropathy secondary to gynecologic malignancies were treated successfully by placement of Wallstent self–expandable intraureteral metallic stents. The patients were followed for a mean period of 15 (range 9–24) months.Results: Obstructive uropathy was resolved in all cases. In 1 patient placement of an additional, totally coaxial, stent was considered necessary because of tumor ingrowth, occurring 6 months after the procedure. In another patient, tumor overgrowth invading the borderline area between the proximal ureteric end and the metallic prosthesis was seen 12 months after stent placement causing obstruction. Thus, an additional Wallstent was implanted overlapping the initially placed stent. Patency was achieved in all the remaining ureters, during the follow–up period, without any need for further intervention.Conclusion: Implantation of self–expandable metal stents is a safe and effective method for bypassing ureteral obstruction due to gynecologic malignancies.

Keywords:
Metal stents, Ureteral obstruction, Ovarian carcinoma, Cervical carcinoma
1.
Van Nagell JR Jr, Donaldson ES, Wood EG: Urinary tract involvement by invasive cervical carcinoma; in Buchsbaum HJ, Schmidt JD (ed): Gynecologic and Obstetric Urology. Philadelphia, Saunders, 1978.
2.
Rose PG: Operative retroperitoneal ureteral catheterization for obstructive uropathy in primary locally advanced carcinoma of the cervix: Description of a technique and experience. Gynecol Oncol 1996;61:79–82.
3.
Delgado G: Urinary conduit diversion in advanced gynecologic malignancies. Gynecol Oncol 1978;6:217–222.
4.
Villani L, Sacco F, Benedetti Panici P, Margariti PA, Bompiani A, Sacco R, Alcini E, Crucitti F: Urinary diversion by ileal conduit in gynecologic oncology. Eur J Gynaecol Oncol 1981;2:108–112.
5.
Soper JT, Blaszczyk TM, Oke E, Clarke–Pearson D, Creasman WT: Percutaneous nephrostomy in gynecologic oncology patients. Am J Obstet Gynecol 1988;158:1126–1131.
6.
Hedegaard CK, Wallace D: Percutaneous nephrostomy: Current indications and potential uses in obstetrics and gynecology. Literature review and report of case. Obstet Gynecol Surv 1987;42:671–675.
7.
Sigwart U, Puel J, Mirkovitch B, Joffre F, Kappenberger L: Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701–706.
8.
Adam A, Chetty N, Roddie M, Yeung E, Benjamin IS: Self–expandable stainless steel endoprostheses for treatment of malignant bile duct obstruction. AJR 1991;156:321–325.
9.
Coons HG: Self–expanding stainless steel biliary stents. Radiology 1990;170(part 2):979– 982.
10.
Machan L, Jager HR, Adam A, Gill K, Williams G, Allison DG: Benign prostatic hypertrophy: Treatment with a metallic stent. AJR 1989;153:779–781.
11.
Milroy EJG, Chapple CR, Cooper JE, Eldin A, Wallsten H, Seddon AM, Rowles PM: A new treatment for urethral strictures. Lancet 1988;i: 1424–1427.
12.
Kirby RS, Heard SR, Miller P, Eardley I, Holmes S, Vale J, Liu S: Use of the ASI titanium stent in the management of bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 1992;148:1195–1198.
13.
Lugmayr H, Pauer W: Self–expanding metal stents for palliative treatment of malignant ureteral obstruction. AJR 1992;159:1091– 1094.
14.
Flueckiger F, Lammer J, Klein GE, Hausegger K, Lederer A, Szolar D, Tamussino K: Malignant ureteral obstruction: Preliminary results of treatment with metallic self–expandable stents. Radiology 1993;186:169–173.
15.
Barbalias GA, Siablis D, Liatsikos EN, Karnabatidis D, Yarmenitis S, Bouropoulos K, Dimopoulos J: Metal stents: A new treatment of malignant ureteral obstruction. J Urol 1997; 158:54–58.
16.
Pauer W, Lugmayr H: Metallic Wallstents: A new therapy for extrinsic ureteral obstruction. J Urol 1992;148:281–284.
17.
Gort HB, Mali WP, van Waes PF, Kloet AG: Metallic self–expandible stenting of a ureteroileal stricture. AJR 1990;155:422–423.
18.
Van Nagell JR Jr, Sprague AD, Roddick JW: The effect of intravenous pyelography and cystoscopy on the staging of cervical cancer. Gynecol Oncol 1975;3:87–90.
19.
Devesa SS: Descriptive epidemiology of cancer of the uterine cervix. Obstet Gynecol 1984; 63:605–609.
20.
Pauer W, Lugmayr H: Self–expanding permanent endoluminal stents in the ureter. 5 years results and critical evaluation. Urologe A 1996; 35:485–489.
21.
Diaz–Lucas EF, Martinez–Torres JL, Mena JF, Martinez OC, Serrano AF, Gomez AZ: Self–expanding Wallstent endoprosthesis for malignant ureteral obstruction. J Endourol 1997;11: 441–447.
22.
Barbalias B, Liatsikos EN, Karnabatidis D, Yarmenitis S, Siablis D: Ureteroileal anastomotic strictures: An innovative approach with metallic stents. J Urol 1998;160:1270–1273.
23.
Shekarriz B, Shekarriz H, Upadhyay J, Banerjee M, Becker H, Pontes JE, Wood DP Jr: Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer 1999;15:998–1003.
24.
Emmert C, Rassler J, Kohler U: Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer. Arch Gynecol Obstet 1997;259:147–151.
25.
Demetriou D, Sebeikat D: Percutaneous nephrostomy in malignant ureteral obstruction. Dtsch Med Wochenschr 1996;121:1526–1530.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.